title: More about osteonecrosis.
authors: Richard D
authors: RD
authors: Finkelman
authors: Mark
authors: M
authors: Clemons
authors: Nathaniel
authors: N
authors: Bouganim
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D000069448:Denosumab; D003729:Dental Care; D004164:Diphosphonates / Q000009:adverse effects*; D004347:Drug Interactions; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D007571:Jaw Diseases / Q000139:chemically induced*; D009910:Oral Hygiene; D010020:Osteonecrosis / Q000139:chemically induced*; D053245:RANK Ligand / Q000009:adverse effects; D012307:Risk Factors; D000077211:Zoledronic Acid
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D053245:RANK Ligand; D000069448:Denosumab; D000077211:Zoledronic Acid